Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C

Medeiros, Lucas Pereira Jorge de; Lima, Mario Barreto Correa; Pires, Marcia Maria Amêndola; Maciel, Alessandra M.A.; Medeiros, Renata; Donadel, Mariana Dermínio; Pereira, Isabela Martins Becattini; Leão, Fábio Marchon; Pires, Luiz Eduardo Amorim Correa Lima; Rzetelna, Helio; Brandão‐Mello, Carlos Eduardo

doi:10.24171/j.phrp.2018.9.2.03

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fatigue is a common complaint in HCV patients and can be considered a debilitating symptom with a negative impact on quality of life [ 10 , 20 , 21 ]. In our study, fatigue symptoms, assessed by the FACIT-F questionnaire, increased by 22 points 12 weeks after the end of treatment compared to baseline, indicating an improvement in fatigue symptoms.…”

Section: Discussionmentioning

confidence: 99%

Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free

2020

View full text Add to dashboard Cite

Introduction Interferon (IFN)-free regimens for the treatment of chronic hepatitis C have shown high rates of sustained virological response (SVR) and improved patient-reported outcomes (PROs). The aim of this study was to evaluate the health-related quality of life (HRQoL) and fatigue of patients with chronic hepatitis C (HCV) treated with IFN-free direct-acting antiviral (DAA) agents that achieved SVR following treatment and identify the predictive factors related to HRQoL. Methods Prospective cohort study that included patients with HCV treated with DAA who obtained an SVR. The patients answered three self-reported questionnaires (PROs): Short Form 36 (SF-36), the Chronic Liver Diseases Questionnaire (CLDQ), and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire at baseline, weeks 6 and 12 of treatment, and at 12 weeks after therapy. Patients were treated with DAA with or without ribavirin (RBV). The PRO scores were compared using analysis of variance (ANOVA). A comparison of PROs and serum hemoglobin levels was performed between the group that used ribavirin and the one that did not use ribavirin using the t student test. Predictive factors were calculated using a multiple linear regression model. Results Among the 113 patients selected, 105 presented an SVR and were included in the study, in which, 54% men, 80% genotype 1, 44% cirrhosis and 46% with RBV. At 12 weeks after the end of treatment, there was a significant improvement in the scores of the patient self-reports (PROs) when compared with baseline for the CLDQ (+10.52%, p<0.001), SF-36-Physical Summary (+19%, p<0.001), and FACIT (+17.34%, p<0.001). Patients who used RBV had worse PROs and serum hemoglobin levels compared to the group that did not use RBV (p<0,05). As predictors of worsening of the PROs we had the presence of diabetes mellitus, liver cirrhosis and HIV co-infected. Conclusion Patients treated with IFN free regimens presents significant improvement in PROs. The presence of diabetes mellitus, cirrhosis, and HIV co-infected has a negative effect on HRQoL before, during and after treatment of hepatitis C. The addition of ribavirin to the antiviral regimens used compromises the HRQoL indexes during antiviral therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free

2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, selectively using 4 questionnaires (Short Form36, Chronic Liver Disease Questionnaire-HCV, Work Productivity, and Activity Index, Functional Assessment of Chronic Illness Therapy-Fatigue) to evaluate patient-reported outcomes before, during, and after DAAs treatment, short form36, Chronic Liver Disease Questionnaire, and FACIT-F scores improved significantly in CHC patients during and post-treatment. [ 37 ]…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination

Li¹,

Jiang

et al. 2020

Medicine

View full text Add to dashboard Cite

Several new, pangenotypic direct-acting antiviral agents (DAAs) have been approved, may reduce the need for genotyping to guide therapy decisions for patients with chronic hepatitis C (CHC). This study aimed to investigate the efficacy and safety of Sofosbuvir (SOF)-based pangenotypic DAAs therapy for CHC patients without genotype (GT determination in the real-world practice. This retrospective cohort study included treatment-naïve CHC patients without GT determination, who received SOF-based DAAs therapy, including 400 mg SOF plus 60 mg daclatasvir (DCV) daily or 400 mg SOF plus 100 mg velpatasvir (VEL) daily for 12 or 24 weeks. Clinical and laboratory data, including sustained virologic response (SVR), were obtained at baseline, end of treatment (EOT), 12 weeks after EOT, and 48 weeks after EOT. A total of 95 CHC patients, including 30 (31.58%) had liver cirrhosis were enrolled. SVR rates after 12 weeks of treatment (SVR12) was 96.84% (92/95), including 96.20% (76/79) of patients receiving SOF plus DCV and 100% (16/16) of patients receiving SOF plus VEL. For 92 patients achieving an SVR12, no virological relapse was observed at 48 weeks after EOT. Furthermore, serum evaluation of liver fibrosis aspartate aminotransferase-to-platelet ratio index and Fibrosis-4 score were decreased significantly at EOT and 12 weeks after EOT, compared to pre-treatment values (both P < .05). Treatment was well-tolerated by our patients. SOF-based pangenotypic DAAs including SOF plus DCV and SOF plus VEL, were effective and safe for CHC patients without GT determination in this study. This may provide a potential simple strategy for CHC treatment without GT determination.

show abstract

Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection

Dalgård

Litwin

Shibolet

et al. 2022

Journal of Addictive Diseases

View full text Add to dashboard Cite

a institute of clinical Medicine, akershus university, oslo, norway; b Prisma Health/university of south carolina school of Medicine Greenville, clemson university, Greenville, sc, usa; c liver unit, department of Gastroenterology, tel aviv Medical center and tel aviv university, tel aviv, israel; d the Kirby institute, unsW sydney, sydney, nsW, australia; e id care, Hillsborough, nJ, usa; f Yale university school of Medicine, new Haven, ct, usa; g vancouver infectious diseases centre,

show abstract

Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C

Cited by 4 publications

References 27 publications

Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free

Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free

Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination

Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection

Contact Info

Product

Resources

About